Predictive value of serum sICAM-1, TSGF and CEA detection for postoperative recurrence of invasive bladder cancer
MEI Yanhui1, WU Yuhai1, MEN Tingting1, LI Gang2, NIU Wenjie1, LIU Shaoqing1,*
1 Department of Urology, Binzhou Medical University Hospital, Binzhou 256600, China; 2 Department of Urology,Second Hospital of Tianjin Medical University
Abstract：Objective： To investigate the predictive value of serum soluble intercellular adhesion molecle-1 (sICAM-1), tumor specific growth factor (TSGF) and carcinoembryonic antigen (CEA) for postoperative recurrence of invasive bladder cancer. Methods： Seventy-five patients with invasive bladder cancer treated with hemicyclic combined with chemotherapy were divided into recurrence group and non-recurrence group according to whether recurrence occurred within 2 years of follow-up. The clinical characteristics and serum sICAM-1, TSGF and CEA levels of two groups were compared and the predictive value of sICAM-1, TSGF and CEA in the recurrence of invasive bladder cancer patients within 2 years was explored. Results： Among the 75 subjects, 26 had recurrence within 2 years after treatment with the recurrence rate being 34.67%. There was no significant difference in gender, age, tumor number and tumor diameter between relapsed group and non-relapsed group (P>0.05). The difference in pathological stage and tissue differentiation between two groups was significant (P<0.05). The levels of sICAM-1, TSGF and CEA in recurrence group were significantly higher than those in non-recurrence group (P<0.05). High serum sicam-1, TSGF and CEA levels were independent risk factors for postoperative recurrence in patients with invasive bladder cancer (P<0.05). The AUC of sICAM-1, TSGF and CEA for the prediction of recurrence of invasive bladder cancer was respectively 0.822, 0.857 and 0.852, with the predictive sensitivity of 69.2%, 73.1%, 76.9% and the specificity of 93.9%, 91.8%, 87.8%. Conclusion： Serum sICAM-1, TSGF and CEA expression levels are higher in patients with recurrent invasive bladder cancer. They have high application value in predicting postoperative recurrence of invasive bladder cancer.
梅延辉, 武玉海, 门婷婷, 李刚, 牛文杰, 刘少青. 三种检测方法对浸润性膀胱癌患者行膀胱部分切除术后复发的预测价值[J]. 微创泌尿外科杂志, 2019, 8(5): 324-328.
MEI Yanhui, WU Yuhai, MEN Tingting, LI Gang, NIU Wenjie, LIU Shaoqing. Predictive value of serum sICAM-1, TSGF and CEA detection for postoperative recurrence of invasive bladder cancer. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2019, 8(5): 324-328.
[1] 薛斌,何秉勋,康厚彬,等.经尿道膀胱肿瘤电切术联合吡柔比星膀胱灌注治疗对浅表性膀胱癌患者预后及血清相关因子的影响.实用癌症杂志,2016,31(6):1027-1029. [2] SOLANKI AA, MARTIN B, KORPICS M, et al.Bladder-preserving therapy patterns of care: a survey of US radiation oncologists. Int J Radiat Oncol Biol Phys, 2017,99(2):383-387. [3] 林英立,李艳丽,戚景光,等.血清中CDH13基因启动子甲基化对非肌层浸润性膀胱癌患者术后复发的预测作用.现代泌尿外科杂志,2017,22(8):576-579. [4] BAZARGANI ST, CLIFFORD TG, DJALADAT HA, et al.Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer. Urol Oncol, 2019,37(1):1-11. [5] 王群,胡卫红,胡乃刚.多柔比星灌注治疗对行TURBT术后浅表性膀胱癌患者临床疗效及相关指标的影响.中国药房,2017,28(36):5091-5094. [6] 钟隆飞,李巧星,王伟录,等.肌层浸润性膀胱癌保留膀胱术后复发与进展的相关因素分析.现代泌尿生殖肿瘤杂志,2017,9(1):17-20. [7] 骆莉萍,吴振启.吡柔比星不同灌注时间治疗表浅性膀胱癌的安全性及疗效比较.中华实用诊断与治疗杂志,2017,31(3):289-290. [8] 辛士永,李亮亮,吴硕,等.吉西他滨联合卡介苗膀胱灌注预防高危非肌层浸润性膀胱癌术后复发的效果.中国老年学杂志,2019,39(5):1064-1068. [9] 王路加,冯陈陈,高鹏,等.尿液BLCA-1与BLCA-4检测对膀胱癌早期无创性诊断和复发监测的价值.现代泌尿生殖肿瘤杂志,2017,9(2):84-88. [10] HIMBERT C, OSE J, LIN TD, et al. Inflammation-and angiogenesis-related biomarkers are correlated with cancer-related fatigue in colorectal cancer patients: Results from the ColoCare Study. Eur J Cancer Care (Engl), 2019,284, SI):e13055. [11] 母健君,白冰,张天德,等.腹腔镜膀胱癌根治术的临床疗效及对患者血清SF,SIL-2R及TSGF水平的影响.现代生物医学进展,2017,17(24):4695-4698. [12] HAYASHI Y, NISHIMURA E, SHIMIZU S, et al.Sigmoidocolocystoplasty for neurogenic bladder reviewed after 20 years. J Pediatr Surg, 2017,52(12):2070-2073. [13] 林晨,刘湘鄂,向俊,等.吡柔比星膀胱灌注对浅表性膀胱癌患者血清sICAM-1,VEGF及MMP-9水平的影响.微创泌尿外科杂志,2018,7(5):346-350. [14] 梅勇,杨旭辉,刘颜,等.完全腹腔镜术治疗老年原发性肝细胞癌的临床疗效及对血清VEGF TGF-α SICAM-1的影响.河北医学,2018,24(12):2032-2037. [15] 陈昌国,陈秋圆.细胞间黏附分子1及血清可溶性细胞间黏附分子1与肿瘤关系的研究进展.国际检验医学杂志,2018,39(11):1370-1374. [16] 刘月芬. Ⅰ期宫颈癌患者化疗前外周血中TSGF,SCC-Ag,CA125水平表达对其预后的评估价值.实用癌症杂志,2019,34(2):321-323.
